Skip to Main Content

Paper Details

N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Cancer Cell
362
2016
CRPC, EZH2, MYCN, N, N-Myc, NEPC, Neuroendocrine Prostate Cancer, Polycomb Repressive Complex 2, androgen, androgen receptor, cancer, castration-resistant prostate adenocarcinoma, human, human NEPC, mouse, neuroendocrine prostate cancer, oncogene, pediatric tumors, prostate cancer
Author NameAffiliation
Himisha BeltranMeyer Cancer Center, USA Englander Institute for Precision Medicine, New York-Presbyterian Hospital
Himisha BeltranMeyer Cancer Center, USA Englander Institute for Precision Medicine, New York-Presbyterian Hospital
Loredana PucaEnglander Institute for Precision Medicine, New York-Presbyterian Hospital
Joanna CyrtaUSA Englander Institute for Precision Medicine, New York-Presbyterian Hospital
Andrea SbonerUSA Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Institute for Computational Biomedicine, NY 10065 USA Tri-Institutional Training Program in Computational Biology and Medicine of Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, and Cornell University
Andrea SbonerUSA Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Institute for Computational Biomedicine, NY 10065 USA Tri-Institutional Training Program in Computational Biology and Medicine of Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, and Cornell University
Theresa Y MacDonald
Theresa Y MacDonald
Cynthia Cheung
Yu ChenMemorial Sloan Kettering Cancer Center
Juan Miguel MosqueraUSA Englander Institute for Precision Medicine, New York-Presbyterian Hospital
Juan Miguel MosqueraUSA Englander Institute for Precision Medicine, New York-Presbyterian Hospital
Brian D RobinsonUSA Englander Institute for Precision Medicine, New York-Presbyterian Hospital
Olivier ElementoMeyer Cancer Center, USA Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Institute for Computational Biomedicine
Olivier ElementoMeyer Cancer Center, USA Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Institute for Computational Biomedicine
Mark A RubinUSA Meyer Cancer Center, USA Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Institute for Computational Biomedicine
Mark A RubinUSA Meyer Cancer Center, USA Englander Institute for Precision Medicine, New York-Presbyterian Hospital, Institute for Computational Biomedicine
Francesca DemichelisEnglander Institute for Precision Medicine, New York-Presbyterian Hospital, University of Trento
Francesca DemichelisEnglander Institute for Precision Medicine, New York-Presbyterian Hospital, University of Trento
David S RickmanUSA Meyer Cancer Center, USA Englander Institute for Precision Medicine, New York-Presbyterian Hospital
  • 1 - 20

Datasets

Release 1.2